Stock comparison
LeMaitre Vascular
Rigel Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 47D | LMAT |
| Benjamin Graham | 89A | 34F | LMAT |
| Philip Fisher | 81C | 54C | LMAT |
| Peter Lynch | 67B | 54C | LMAT |
| Joel Greenblatt | 56D | 48D | LMAT |
| Charlie Munger | 68D | 62D | LMAT |
| Terry Smith | 69D | 61C | LMAT |
Side-by-side metrics
| Metric | LMAT | RIGL |
|---|---|---|
| Market cap | $2.23B | $536.75M |
| P/E (TTM) | 37.1x | 1.4x |
| EV/EBIT | 36.6x | 4.3x |
| ROIC (TTM) | 9.43% | 27.96% |
| Gross margin | 72.39% | 93.39% |
| Net margin | 24.35% | 121.51% |
| Revenue CAGR 5y | 12.75% | 18.5% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $536.75M+76%
RIGL leads on
- P/E (TTM)1.4xvs 37.1x+96%
- EV/EBIT4.3xvs 36.6x+88%
- Net margin121.51%vs 24.35%+80%
- Debt / Equity0.1xvs 0.5x+76%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.